Depth and durability of response with TGF-β trapping in recurrent or metastatic (R/M) HPV-negative head and neck squamous cell carcinoma (HNSCC): Long-term results from two expansion cohorts of a phase 1/1b study of ficerafusp alfa plus pembrolizumab.

ficerafusp alfa (BCA101) - Bicara Therapeutics

Keytruda (pembrolizumab) - Merck (MSD)

https://www.asco.org/abstracts-presentations/263363

Deborah Wong; Susannah Calhoun; Ling Gao; Farnoush Safavi; Zhao Yang; John Kaczmar; Christine Chung; Glenn Hanna; Dan Zandberg; Tamara Sussman; Eric Sherman; Neal Akhave; Assuntina Sacco; Ariel Birnbaum

Apr 21, 2026